Abedin Sameem, Yanik Gregory A, Braun Thomas, Pawarode Attaphol, Magenau John, Goldstein Steven C, Levine John E, Kitko Carrie L, Couriel Daniel R
Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Blood and Marrow Transplant Program, University of Michigan Health System, Ann Arbor, Michigan.
Biol Blood Marrow Transplant. 2015 Jun;21(6):1127-31. doi: 10.1016/j.bbmt.2015.02.006. Epub 2015 Feb 14.
Bronchiolitis obliterans syndrome (BOS) is a significant post-transplant complication with low survival. BOS stage 0p (BOS 0p) is a parameter detected on pulmonary function tests (PFTs) after lung transplantation to identify patients at risk to develop BOS. We performed a retrospective study on 442 patients who underwent allogeneic stem cell transplant from 2007 to 2011 to evaluate whether development of BOS 0p is a risk factor in this population for BOS. Patients who met criteria for BOS 0p were significantly more likely to develop BOS (hazard ratio [HR], 3.22; P < .001). BOS 0p was significantly associated with a history of lung disease pretransplant (HR, 2.48; P = .001) and chronic graft-versus-host disease (GVHD) outside the lung post-transplant (HR, 23; P < .001). Finally, BOS 0p criteria were adequately sensitive in predicting BOS (85%), with a high negative predictive value (98%). Our findings suggest a routine PFT screening strategy with the intent of detecting BOS 0p, especially among patients with prior lung disease and who developed chronic GVHD, could suitably identify an at-risk population for the development of BOS.
闭塞性细支气管炎综合征(BOS)是一种严重的移植后并发症,生存率较低。BOS 0p期是肺移植后肺功能测试(PFT)检测到的一个参数,用于识别有发生BOS风险的患者。我们对2007年至2011年接受异基因干细胞移植的442例患者进行了一项回顾性研究,以评估BOS 0p的发生是否是该人群发生BOS的危险因素。符合BOS 0p标准的患者发生BOS的可能性显著更高(风险比[HR],3.22;P <.001)。BOS 0p与移植前肺部疾病史(HR,2.48;P =.001)和移植后肺部以外的慢性移植物抗宿主病(GVHD)显著相关(HR,23;P <.001)。最后,BOS 0p标准在预测BOS方面具有足够的敏感性(85%),阴性预测值较高(98%)。我们的研究结果表明,旨在检测BOS 0p的常规PFT筛查策略,特别是在有既往肺部疾病且发生慢性GVHD的患者中,可以适当地识别出有发生BOS风险的人群。